Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Industry: Healthcare

Listed 5 Consecutive Market Days. On List as of 04/03/2012 Through 04/11/2012

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Current Quote*
Last: $3.240
Change: 0.040
Book: $10.389
Volume: 24,192

As Of: 03/22 16:21 ET
*Quotes delayed by 20min.

Graphs for BCLI

3 Month Graph

6 Month Graph

1 Year Graph